Stockholm3 launched in Germany

A3P Biomedical and Labor Dr. Wisplinghoff, one of Germany’s largest and most renowned medical laboratories, are excited to announce that Stockholm3, for early detection of prostate cancer, has now been launched and is available in Germany.

Prostate cancer is the most common cancer among men worldwide, with a significant need for improved early detection and treatment. The partnership between A3P Biomedical and Labor Dr. Wisplinghoff marks a milestone in advancing prostate cancer diagnostics in Germany, offering Stockholm3 as an innovative solution to enhance accuracy in diagnosing significant prostate cancers early, as well as reducing unnecessary MRIs and biopsies.

“We are thrilled to partner with Labor Dr. Wisplinghoff in bringing Stockholm3 to Germany,” says Martin Steinberg, Executive Chairman of A3P Biomedical.

“Our vision is to redefine the standard of care for prostate cancer diagnostics. Stockholm3 has demonstrated both higher sensitivity and specificity compared to PSA testing, leading to earlier detection of aggressive cancers and reducing unnecessary procedures. Germany represents a key market for us, and we are confident that this partnership will make a significant impact on patient outcomes,” Martin Steinberg continues.

“Partnering with A3P Biomedical allows us to bring Stockholm3, a groundbreaking innovation in prostate cancer diagnostics, to Germany,” says Dr. Fabian Wisplinghoff, Managing Partner at Labor Dr. Wisplinghoff.

“By offering this advanced test, we can identify aggressive prostate cancers earlier, enabling timely treatment decisions and improving patient outcomes, while also minimizing unnecessary procedures. We are proud to lead the way in enhancing prostate cancer care across the country,” Dr. Fabian Wisplinghoff concludes.

For more details on Stockholm3, please visit www.stockholm3.com, and for information on how to order the test, please visit www.wisplinghoff.de/stockholm3.

About Labor Dr. Wisplinghoff

Labor Dr. Wisplinghoff improves patient care by providing the highest quality laboratory diagnostics to hospitals, medical practices, universities, health departments, and other medical entities 24/7/365. Founded in 1977 by Dr. Uta Wisplinghoff, it has become one of the largest independent private medical laboratories in Western Europe. Based in Cologne, Germany, the laboratory offers comprehensive testing capabilities to national and international clients, covering all areas of clinical pathology with experienced board-certified medical specialists. It is accredited according to DIN EN ISO 15189, ensuring the highest standards in medical laboratory quality and competence.

For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/

Links